Search results
Results from the WOW.Com Content Network
Empagliflozin, sold under the brand name Jardiance (/ ˈ dʒ ɑːr d i ə n s / JAR-dee-əns), among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes. [12] [2] [14] It is taken by mouth. [2]
Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. [30] Of the gliflozins, empagliflozin and tofogliflozin have the highest specificity for SGLT2 inhibition. [1] This oral medicine for type 2 diabetes has been shown to reduce the risk of cardiovascular death. [31]
To reduce the risk of developing ketoacidosis (a serious condition where the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medications, recommending they be temporarily stopped before scheduled surgery.
In the trial, Jardiance cut the combined risk of cardiovascular death or hospitalization from heart failure in HFpEF patients with or without diabetes. At the 26-month mark, 13.8% of Jardiance ...
In a statement on Friday, the two partners said Jardiance cut the risk of kidney disease progression and cardiovascular death by 28%, citing results from a late-stage trial which included people ...
"The list price does not reflect the rebates, discounts, and fees that Novo Nordisk provides to lower the list price, nor does it reflect the numerous other costs in the system that ultimately ...
In the European Union empagliflozin/metformin is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control: [5]
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.